On this page
Elrexfio
elranatamab-bcmm
351(a) Standalone BLA
Overview
Source: Purple BookProprietary name
Elrexfio
Proper name
elranatamab-bcmm
Licence type
351(a)
BLA number
761345
Applicant
Pfizer Inc.
Center
CDER
Presentations
2
First licensure
—
Presentations
Source: Purple Book| Strength | Dosage form | Route | Presentation | Status | Licensed |
|---|---|---|---|---|---|
| 44MG/1.1ML (40MG/ML) | Injection | Subcutaneous | Single-Dose Vial | Rx | August 14, 2023 |
| 76MG/1.9ML (40MG/ML) | Injection | Subcutaneous | Single-Dose Vial | Rx | August 14, 2023 |
Exclusivity
Source: Purple Book| Kind | Expires |
|---|---|
| Orphan exclusivity | August 14, 2030 |
Sources for this page
| Purple Book | FDA | Licence type, presentations, reference product, exclusivity |